CVS at a glance
CVS Health (CVS, SEC CIK 64803) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CVS Health (CVS) reported revenue of $402.1 billion (up 7.8% from FY2024) and net income of $1.8 billion. Diluted EPS was $1.39.
- As of September 30, 2026, 56 institutional investment managers tracked by SignalX reported holding CVS Health (CVS) shares worth $41.3 billion in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Shah Prem S on November 6, 2026 of 23,855 shares at $83.89 per share.
- In the last 90 days, CVS insiders reported 1 open-market purchase ($2.0M) and 0 open-market sales ($0) on Form 4, a net purchase of $2.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $402.1B
- +7.8% vs prior year
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$2.0M
- 13F holders
- 56 funds
- $41.3B · −5 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business risk focus on compliance with extensive laws, regulations, and contractual requirements in healthcare sectors
- Increased litigation exposure due to vertical integration strategy and expanded healthcare services
- Ongoing costly class action, qui tam, securities, and derivative litigation with potential high damages, not fully insured
- Heightened regulatory audits, inspections, government inquiries, and legal proceedings inside and outside U.S.
- Insurance coverage limits highlighted with risks of unavailable or insufficient insurance, especially for punitive damages
Risk Factors
- Opioid litigation risk: $320 million accrual increase for ongoing opioid litigation matters in 2025
- Geopolitical/macroeconomic exposure: Medicare Advantage segment served 37 million people, sensitive to CMS policy changes
- Supply chain vulnerability: Reliance on pharmaceutical pricing negotiations through group purchasing organization for drug cost management
- Competitive risk: Health Services segment faces disruption from Signify Health and Oak Street Health in value-based primary care
- Financial risk: $5.7 billion goodwill impairment in Health Care Delivery reporting unit in 2025 impacting operating income
Management Discussion & Analysis
- Market valuation risk: $3.6B fair value decline in long-term debt with 100bp rate increase; no impact on operations
- Interest rate sensitive investment net fair value decline approx. $765M, recorded as unrealized loss in equity
- No material foreign currency or commodity derivative exposures as of Dec 31, 2025
- Cybersecurity risks ongoing; no material impact on operations; significant resources allocated to risk mitigation
AI summary of the CVS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added separation risk triggered by November 4, 2026 announcement to create CVS Health and CVS Pharmacy
- Operational risk: management distraction from separation could disrupt ongoing business and adversely affect results
- Regulatory and tax risk: separation requires SEC Form 10 effectiveness and confirmation of tax-free treatment
- Execution risk: separation expected first half of 2028, subject to Board approval and independent-company readiness
- Financial risk: dis-synergy, restructuring and transaction costs could exceed estimates
Management Discussion & Analysis
- Revenue $108.4B, up 5.4% YoY from $102.9B, driven by Health Services and Health Care Benefits
- Operating margin 3.3% vs (3.1)% YoY, with operating income $3.6B vs $3.2B loss
- Best segment Health Services: revenue $54.0B, up 9.5%; adjusted operating margin 3.9% vs 4.2%
- Worst segment Pharmacy & Consumer Wellness: revenue $35.5B, down 2.0%; adjusted operating margin 4.6% vs 4.1%
- Cash $11.7B; nine-month operating cash flow $15.3B, up $8.1B, with $5.5B investing outflows and no share repurchases
- Outlook headwinds: elevated utilization, PBM pricing pressure, regulatory changes, inflation, tariffs and weaker discretionary spending
AI summary of the CVS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Planned tax-free separation by first half 2028 into CVS Health healthcare solutions and CVS Pharmacy retail operations
- CVS Health to include Aetna, Caremark, Specialty, Oak Street Health and Signify Health
Item 7.01: Regulation FD Disclosure
- CVS intends to separate into two independent, publicly traded companies
- Transaction structured to be tax-free for CVS and shareholders under U.S. federal income tax rules
Item 2.02: Results of Operations and Financial Condition
- CVS Health reported results for the three months ended September 30, 2026
- Press release issued November 4, 2026, with financial details in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $108.4B, up 5.4% YoY, with adjusted operating income rising 21.2% to $4.2B
- Adjusted EPS $2.09, up from $1.60, driven primarily by Health Care Benefits margin recovery
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Larry M. Robbins resigned from CVS Health’s Board effective August 13, 2026
- Resignation unrelated to disagreements over company operations, policies, or practices
Item EX-99.1: Item EX-99.1
- Teresa Heitsenrether joins CVS’s Board effective November 18, 2026, adding data, analytics, AI and technology-transformation expertise
- Heitsenrether’s JPMorgan operating background supports CVS’s stated strategy to become a consumer-focused health technology company
Item 7.01: Regulation FD Disclosure
- Board appointment of Ms. Heitsenrether, adding a new director to CVS Health’s oversight structure
- Mr. Robbins’s board resignation, reducing the current director roster and potentially changing board dynamics
AI summaries of CVS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CVS
Don't miss the next CVS filing
- Alerts as it files. A push when CVS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CVS, by share count.
- Ask anything. An AI agent that reads every CVS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Shah Prem S | Buy | Nov 6, 2026 | 23,855 | $83.89 |
| Clark James David | F | Jun 26, 2026 | 454 | $90.98 |
| Newman Brian | F | May 31, 2026 | 2,478 | $90.98 |
| Compton-Phillips Amy | F | May 31, 2026 | 7,618 | $90.98 |
| Shulman Douglas H. | A | May 14, 2026 | 1,447.504 | $97.15 |
| Norwalk Leslie V | A | May 14, 2026 | 1,447 | $97.15 |
| Clark James David | F | Apr 1, 2026 | 3,262 | $72.49 |
| Shah Prem S | F | Apr 1, 2026 | 1,484 | $72.49 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $372.8B | $402.1B |
| Operating Income | - | $8.5B | $4.7B |
| Net Income | $8.3B | $4.6B | $1.8B |
| Op. Margin | - | 2.3% | 1.2% |
| Net Margin | - | 1.2% | 0.4% |
| Balance Sheet | |||
| Total Assets | - | $253.2B | $253.5B |
| Equity | $76.5B | $75.6B | $75.2B |
| ROE | 10.9% | 6.1% | 2.4% |
| Per Share | |||
| EPS | $6.47 | $3.66 | $1.39 |
| Cash Flow | |||
| Operating CF | - | $9.1B | $10.6B |
| CapEx | $3.0B | $2.8B | $2.8B |
Source: XBRL data in CVS Health (CVS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CVS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 56 | $41.35B |
| Q2 2026 | 61 | $54.06B |
| Q1 2026 | 55 | $37.08B |
| Q4 2025 | 54 | $42.19B |
| Q3 2025 | 59 | $43.97B |
| Q2 2025 | 54 | $37.42B |
| Q1 2025 | 55 | $25.74B |
| Q4 2024 | 50 | $13.89B |
- Renaissance Technologies LLC+2.28M (+518%)
- Invesco Ltd+1.03M (+5%)
- Ameriprise Financial+911.9K (+11%)
- Citigroup+835.3K (+46%)
- Truist Financial+530.4K (+32%)
- Citadel Advisors LLC−4.00M (-83%)
- Franklin Resources−3.60M (-36%)
- BlackRock−2.83M (-2%)
- T. Rowe Price Group−2.54M (-10%)
- Millennium Management−669.6K (-31%)
- Two Sigma Investments+134.6K
- Marex Group plc+9.0K
- FMR LLC (Fidelity)−28.92M
- Viking Global Investors−3.66M
- Equitable Holdings Inc−50.4K
- Blackstone Group−9.3K
- Northwest Bancshares, Inc.−2.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 444 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CVS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 6, 2026 | - | - | - |
| 13F-HR | Nov 5, 2026 | Sep 30, 2026 | - | |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 13F-HR | Aug 6, 2026 | Jun 30, 2026 | - | |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 8-K | May 18, 2026 | - | Analysis | |
| 4 | May 15, 2026 | - | - | |
| 4 | May 15, 2026 | - | - | |
| 13F-HR | May 7, 2026 | Mar 31, 2026 | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
| 4 | Apr 2, 2026 | - | - | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ABSI · Absci CorpServices-Commercial Physical & Biological Research
- ACHC · Acadia Healthcare Company IncServices-Specialty Outpatient Facilities, NEC
CVS SEC filings: frequently asked questions
Are CVS insiders buying or selling?
In the last 90 days, CVS Health (CVS) officers, directors and 10% owners reported 1 open-market purchase worth $2.0 million by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CVS stock?
As of September 30, 2026, the largest CVS Health (CVS) holders among the 13F filers tracked by SignalX were BlackRock ($10.3 billion), Vanguard Capital Management LLC ($7.2 billion), State Street Corp ($5.1 billion), Vanguard Portfolio Management LLC ($2.3 billion), Bank of America Corp ($2.0 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CVS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CVS Health (CVS) reported revenue of $402.1 billion (up 7.8% from FY2024) and net income of $1.8 billion. Diluted EPS was $1.39. The figures come from the XBRL data in the 10-K.
What are the main risks in CVS's latest 10-K?
In the 10-K filed February 10, 2026, CVS Health (CVS) flagged: Opioid litigation risk: $320 million accrual increase for ongoing opioid litigation matters in 2025. Geopolitical/macroeconomic exposure: Medicare Advantage segment served 37 million people, sensitive to CMS policy changes. (AI summary of the Risk Factors section.)
What did CVS report in its latest 8-K?
CVS Health (CVS) filed an 8-K on November 4, 2026 reporting Item 7.01 (Regulation FD Disclosure). Planned tax-free separation by first half 2028 into CVS Health healthcare solutions and CVS Pharmacy retail operations.
What are the latest CVS SEC filings?
CVS Health (CVS) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 6, 2026.
What is CVS's SEC CIK number?
CVS Health (CVS)'s SEC Central Index Key (CIK) is 64803. EDGAR lists every CVS filing under that number.
Ask anything about CVS
The research agent reads CVS's filings, financials, insider trades and 13F holders, then answers with sources.